View Older Stories View More Recent Stories

Jul 18, 2025 08:30AM MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
May 13, 2025 04:05PM MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
Feb 12, 2025 04:12PM MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
Nov 12, 2024 04:05PM MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Sep 19, 2024 04:02PM MEI Pharma (MEIP) Reports End of Year 2024 Cash Position
Sep 19, 2024 04:01PM MEI Pharma Reports Fiscal Year End 2024 Cash Position
Aug 12, 2024 08:31AM MEI Pharma (MEIP) Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
Aug 12, 2024 08:30AM MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
Jul 22, 2024 08:32AM MEI Pharma (MEIP) to Consider Strategic Alternatives
Jul 22, 2024 08:30AM MEI Pharma to Consider Strategic Alternatives
May 9, 2024 04:02PM MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
Apr 11, 2024 08:03AM MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
Apr 11, 2024 08:02AM MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344
Apr 11, 2024 08:02AM MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Apr 11, 2024 08:00AM MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Apr 10, 2024 08:00AM MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Mar 26, 2024 08:01AM MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax
Mar 26, 2024 08:00AM MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Feb 13, 2024 05:05PM MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Jan 16, 2024 05:00PM MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Dec 11, 2023 12:03PM MEI Pharma (MEIP) Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
Dec 11, 2023 12:00PM MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
Nov 9, 2023 04:05PM MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
Nov 8, 2023 08:00AM MEI Pharma to Present at the Stifel 2023 Healthcare Conference
Nov 6, 2023 04:57PM MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
Nov 2, 2023 09:00AM MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
Nov 1, 2023 09:00AM MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
Oct 17, 2023 05:33PM MEI Pharma Recommends Stockholders Not to Consent
Oct 2, 2023 06:04AM MEI Pharma (MEIP) adopts limited-duration stockholder rights plan following Anson and Cable Car's 13D
Oct 2, 2023 06:00AM MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
Sep 28, 2023 05:00PM MEI Pharma (MEIP) Statement Regarding Anson and Cable Car’s Opportunistic Actions
Sep 28, 2023 05:00PM MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
Sep 26, 2023 04:02PM MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
Sep 21, 2023 08:00AM MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
Sep 18, 2023 08:02AM MEI Pharma (MEIP) Confirms Receipt of Director Nominations From Anson and Cable Car
Sep 18, 2023 08:00AM MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
Aug 16, 2023 08:00AM MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
Jul 23, 2023 02:30PM MEI Pharma Announces Results of Special Meeting of Stockholders
Jul 19, 2023 08:00AM MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
Jul 18, 2023 09:01AM MEI Pharma (MEIP) Responds to Anson and Cable Car
Jul 18, 2023 09:00AM MEI Pharma Responds to Anson and Cable Car
Jul 17, 2023 08:00AM MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
Jul 13, 2023 04:06PM MEI Pharma (MEIP) Postpones Special Meeting
Jul 13, 2023 04:05PM MEI Pharma Postpones Special Meeting of Shareholders
Jul 11, 2023 08:00AM MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
Jul 7, 2023 08:00AM MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
Jul 5, 2023 08:00AM MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
Jun 29, 2023 08:02AM MEI Pharma (MEIP) Issues Letter to Shareholders
Jun 29, 2023 08:00AM MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
Jun 27, 2023 05:15PM MEI Pharma (MEIP) Responds to Anson and Cable Car
View More Recent Stories View Older Stories